Charcot Marie Tooth Disease News and Research

RSS
Charcot-Marie-Tooth disease is a group of progressive disorders that affect the peripheral nerves. Peripheral nerves connect the brain and spinal cord to muscles as well as sensory cells that detect sensations such as touch, pain, heat, and sound.
New U-M hESC lines now available for federally-funded research

New U-M hESC lines now available for federally-funded research

Study describes new family of six genes that control mitochondrial transport in neurons

Study describes new family of six genes that control mitochondrial transport in neurons

New measurement tool for clinical trials to help children with Charcot-Marie-Tooth disease

New measurement tool for clinical trials to help children with Charcot-Marie-Tooth disease

U-M’s second human embryonic stem cell line now available for federally-funded research

U-M’s second human embryonic stem cell line now available for federally-funded research

Genetically modified mouse mimics key features of Charcot-Marie-Tooth disease

Genetically modified mouse mimics key features of Charcot-Marie-Tooth disease

U-M's first human embryonic stem cell line to be placed on the U.S.NIH registry

U-M's first human embryonic stem cell line to be placed on the U.S.NIH registry

Damaged mitochondria equivalent to an environmental disaster in the cell

Damaged mitochondria equivalent to an environmental disaster in the cell

Pharnext puts together €2.5M to fund development of Pleodrug for Charcot-Marie-Tooth disease

Pharnext puts together €2.5M to fund development of Pleodrug for Charcot-Marie-Tooth disease

World's best genetic map now built in African-Americans

World's best genetic map now built in African-Americans

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

OSEO awards €10.4 million to DIPPAL project targeting Alzheimer's disease

OSEO awards €10.4 million to DIPPAL project targeting Alzheimer's disease

Study finds genetic change in chromosome 4 causes FSHD

Study finds genetic change in chromosome 4 causes FSHD

Muscular Dystrophy Association awards $14.1M in new grants

Muscular Dystrophy Association awards $14.1M in new grants

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Pharnext closes €4.8-million Series A funding round

Pharnext closes €4.8-million Series A funding round

MDA awards over $21M in grants for advancing critical neuromuscular research

MDA awards over $21M in grants for advancing critical neuromuscular research

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

MDA awards 42 medical researchers and labs over $21M for critical neuromuscular research

MDA awards 42 medical researchers and labs over $21M for critical neuromuscular research

Muscular dystrophy: $1M grant for study of erectile dysfunction drugs in improving muscle blood flow

Muscular dystrophy: $1M grant for study of erectile dysfunction drugs in improving muscle blood flow

Cardiologist receives grant to study impact of erectile dysfunction drugs on muscular dystrophy patients

Cardiologist receives grant to study impact of erectile dysfunction drugs on muscular dystrophy patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.